United Therapeutics Corporation (UTHR) CEO Martine A. Rothblatt Sells 1,258 Shares
United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,258 shares of the stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $122.08, for a total value of $153,576.64. Following the completion of the transaction, the chief executive officer now owns 2,327 shares of the company’s stock, valued at approximately $284,080.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
United Therapeutics Corporation (UTHR) traded down 0.18% during midday trading on Friday, hitting $120.79. The company had a trading volume of 843,120 shares. The stock has a 50 day moving average price of $129.05 and a 200-day moving average price of $129.99. The stock has a market capitalization of $5.25 billion, a PE ratio of 14.01 and a beta of 1.52. United Therapeutics Corporation has a 52 week low of $110.90 and a 52 week high of $169.89.
United Therapeutics Corporation (NASDAQ:UTHR) last announced its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.61 by ($4.86). United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The business had revenue of $444.60 million for the quarter, compared to analyst estimates of $391.53 million. During the same period in the prior year, the company earned $4.42 earnings per share. The company’s quarterly revenue was up 7.8% on a year-over-year basis. On average, equities analysts predict that United Therapeutics Corporation will post $10.09 EPS for the current year.
Large investors have recently made changes to their positions in the stock. Comerica Bank increased its position in United Therapeutics Corporation by 1.3% during the 2nd quarter. Comerica Bank now owns 35,249 shares of the biotechnology company’s stock valued at $4,635,000 after buying an additional 458 shares in the last quarter. JPMorgan Chase & Co. increased its position in United Therapeutics Corporation by 1.8% during the 1st quarter. JPMorgan Chase & Co. now owns 122,497 shares of the biotechnology company’s stock valued at $16,583,000 after buying an additional 2,223 shares in the last quarter. State of Wisconsin Investment Board acquired a new position in United Therapeutics Corporation during the 2nd quarter valued at about $5,256,000. Clarity Capital KCPS Ltd. acquired a new position in United Therapeutics Corporation during the 1st quarter valued at about $230,000. Finally, River & Mercantile Asset Management LLP acquired a new position in United Therapeutics Corporation during the 2nd quarter valued at about $908,000.
A number of equities analysts have issued reports on the company. BidaskClub downgraded United Therapeutics Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of United Therapeutics Corporation in a report on Friday, September 8th. ValuEngine downgraded United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Zacks Investment Research cut United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Finally, Jefferies Group LLC reissued a “sell” rating and issued a $105.00 target price on shares of United Therapeutics Corporation in a research note on Friday, July 14th. Six equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $134.50.
United Therapeutics Corporation Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.